For Healthcare Professionals: Soft Tissue Sarcoma

Over the past two decades, Memorial Sloan Kettering's multidisciplinary team of experts has surgically treated more than 8,000 individuals with soft tissue sarcomas – one of the rarest of cancers – and has provided consultations to almost twice that number. The Soft Tissue Sarcoma Disease Management Team includes specialists in surgery, medical oncology, radiation oncology, diagnostic radiology, nursing, pathology, biostatistics, immunology, epidemiology, and psychiatry.

In pioneering advances in limb-sparing operations that combine radiation therapy and/or chemotherapy, we offer a high rate of tumor control without the need for amputation in many cases. Our physicians and researchers in the laboratory are simultaneously investigating new types of adjuvant treatments for this cancer, including novel chemotherapy agents designed to inhibit tumorigenesis by targeting the tumor cell cycle.

Refering a Patient

Call 866-316-8529
Mon–Fri, 8:30 AM–5:30 PM, ET

Find an Expert | See Clinical Trials | Request a Pathology Consult

#MSKthanks
MSK Named #1 by U.S. News

U.S. News & World Report named Memorial Sloan Kettering the top hospital for cancer care in the nation. We're honored, and patient care will always be our top priority.

#MSKthanks
Prediction Tools

Our online nomograms can be used to predict which approaches to treating soft tissue sarcoma will result in the greatest benefit. Results can help physicians and patients make the best treatment decisions.

Pictured: Murray Brennan
Soft Tissue Sarcoma Information for Your Patients

The Memorial Sloan Kettering approach to diagnosis and treatment of soft-tissue sarcoma in patient-friendly language.

Pictured: Murray Brennan

E-Publications for Medical Professionals

Stay up-to-date on Memorial Sloan Kettering advances in your areas of interest.

Subscribe to OncoNotes »

Pictured: Ping Chi
Combination Therapy for Patients with Untreated Advanced GIST

Medical oncologists William Tap and Ping Chi describe an investigational combination therapy for untreated advanced gastrointestinal stromal tumors.

Pictured: William Tap
Phase III Clinical Trial of Doxorubicin Alone or in Combination with TH-302

Medical oncologist William Tap discusses a multicenter randomized study that compares doxorubicin plus TH-302 versus doxorubicin alone for locally advanced soft tissue sarcoma that is inoperable or metastatic.

Pictured: Ping Chi
GIST Therapy
Pictured: William Tap
Doxorubicin Trial